Brainstorm Cell Therapeutics Inc ALS One Research Symposium Transcript
(audio in progress) who is the Chief Development Officer at Brainstorm, is going to discuss the relationship between CSF biomarkers and treatment efficacy of NurOwn [stem cell therapy].
Thank you, Bob, and thank you for the opportunity to share insights into the rich biomarker data from our Phase 3 trial. It's important that I provide some context before I go into the objectives for today and the results because the broader context of the trial actually drive some of our objectives. And as we publish this trial, you'll likely be aware that this trial included participants with advanced ALS, resulting in participants hitting a floor effect on the ALSFRS-R.
As you can see by the footnote on this on the slide, about a quarter of participants had ALSFRS-R values of 25 or below at baseline. And how the patient population from our Phase 3 trial compares to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |